AI assistant
Sending…
AMGEN INC — Director's Dealing 2025
Mar 6, 2025
29819_dirs_2025-03-05_c480c1cb-0f61-4179-bee1-30d53f74d414.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2025-03-03
Reporting Person: Bradway Robert A (Director, Chairman, CEO and President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-03 | Common Stock | A | 25734 | — | Acquired | 599925 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 90000 | Indirect |
| Common Stock | 90000 | Indirect |
Footnotes
F1: These shares include 2,477 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
More from AMGEN INC
Regulatory Filings
2026
May 20
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 1
Regulatory Filings
2026
Apr 30
Major Shareholding Notification
2026
Apr 29
Regulatory Filings
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 21
Proxy Solicitation & Information Statement
2026
Apr 15
Proxy Solicitation & Information Statement
2026
Apr 7
Proxy Solicitation & Information Statement
2026
Apr 7